Novo Nordisk A/S $NVO Shares Bought by QV Investors Inc.

QV Investors Inc. grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1,539.1% in the second quarter, HoldingsChannel reports. The fund owned 126,114 shares of the company’s stock after buying an additional 118,420 shares during the quarter. QV Investors Inc.’s holdings in Novo Nordisk A/S were worth $8,704,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Copeland Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after acquiring an additional 255 shares during the last quarter. North Capital Inc. acquired a new position in shares of Novo Nordisk A/S during the 1st quarter valued at about $27,000. Stone House Investment Management LLC acquired a new position in shares of Novo Nordisk A/S during the 1st quarter valued at about $30,000. Disciplina Capital Management LLC increased its position in Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 297 shares in the last quarter. Finally, Dagco Inc. acquired a new stake in Novo Nordisk A/S during the 1st quarter worth approximately $35,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on NVO shares. Weiss Ratings reissued a “hold (c)” rating on shares of Novo Nordisk A/S in a research report on Tuesday, October 14th. Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. BNP Paribas raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Finally, HSBC set a $70.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $76.00.

Novo Nordisk A/S Stock Down 0.4%

Shares of NYSE:NVO opened at $53.02 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $114.19. The company has a 50 day moving average of $56.56 and a two-hundred day moving average of $62.40. The company has a market capitalization of $236.74 billion, a price-to-earnings ratio of 14.57, a price-to-earnings-growth ratio of 2.41 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. As a group, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio is 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.